Peripheral NMDA Receptor Antagonists for PAH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary arterial hypertension (PAH) are limited by severe side effects and lack of effective anti-remodeling strategies, with existing NMDA receptor blockers unable to target peripheral receptors without causing central nervous system side effects, necessitating the development of novel peripheral NMDA receptor antagonists that do not cross the blood-brain barrier.
Innovation Solution
Development of cationic compounds with specific chemical modifications to memantine and adamantine derivatives that selectively block peripheral NMDA receptors without brain penetration, utilizing a three-step synthesis strategy to achieve compounds with low brain penetration and effective peripheral NMDA receptor antagonism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing NMDA receptor blockers are used to treat pulmonary arterial hypertension, then peripheral NMDA receptors are blocked, but central nervous system side effects occur due to brain penetration
Solution Approach 1:
The patent applies segmentation by dividing the NMDA receptor blocking action into two distinct compartments: peripheral (therapeutic) and central (toxic). This is achieved through chemical modification of memantine and adamantine derivatives to create compounds that are selectively distributed to peripheral tissues while excluded from the brain by the blood-brain barrier, thus segmenting the pharmacological effect by location.
Solution Approach 2:
The patent implements local quality by endowing different spatial regions with different pharmacological properties. The modified compounds exhibit high NMDA receptor affinity in peripheral tissues (lung, vasculature) while maintaining low or zero concentration in the brain, creating location-specific therapeutic activity that avoids central nervous system toxicity.
2Stress or pressure
If conventional PAH treatments are used to decrease pulmonary vascular resistance, then pulmonary vasodilation is achieved, but anti-remodeling effects are insufficient leading to disease progression
Solution Approach 1:
The patent extracts the anti-remodeling therapeutic effect from the limitations of conventional PAH treatments. By targeting NMDA receptors in pulmonary vascular smooth muscle cells and endothelial cells, the invention isolates a specific molecular pathway that drives vascular remodeling, separating this mechanism from the general vasodilation approach and providing targeted anti-remodeling therapy.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of known NMDA receptor antagonists (memantine and adamantine derivatives) to optimize their pharmacokinetic properties. Specifically, the compounds are designed with molecular features that limit brain penetration while maintaining peripheral NMDA receptor affinity, changing the distribution parameters to achieve selective peripheral action.
3Reliability
If NMDA receptor blockers with high brain penetration are used, then strong peripheral NMDA receptor antagonism is achieved, but severe central nervous system toxicity occurs
Solution Approach 1:
The patent uses the blood-brain barrier as an intermediary element to mediate between the therapeutic need for peripheral NMDA receptor blockade and the avoidance of central nervous system toxicity. The modified compounds are designed to be transported or retained in peripheral compartments while being excluded by the blood-brain barrier, which acts as a selective mediator separating therapeutic from toxic effects.
Data Source
AI summary
The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.